JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
13/10/26 - 13:00
Diasorin obtained FDA approval for Human Parvovirus B19 IgM and IgG on the Liaison XL (334.34 KB)
02/10/26 - 14:22
Margherita Sacerdoti appointed Investor Relations & ESG Senior Director at Diasorin (151.77 KB)
31/07/26 - 12:50
Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
19/06/26 - 15:45
Diasorin Announces FDA 510(K) Clearance and CLIA Waiver for the LIAISON NES Group A Streptococcus (GAS) Assay (174.02 KB)
20/05/26 - 11:16
Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
19/05/26 - 19:23
Diasorin Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay (179.61 KB)
08/05/26 - 17:54
Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
04/05/26 - 17:45
Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President (158.42 KB)
29/04/26 - 15:52
Shareholders' Meeting 2026 (166.06 KB)
07/04/26 - 10:05
Communication on total amount of voting rights (7 April 2026) (225.44 KB)
20/03/26 - 17:44
Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
19/03/26 - 9:47
Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform (234.16 KB)
24/02/26 - 7:06
Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN (154.8 KB)
03/02/26 - 12:13
Diasorin submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver (130.94 KB)
29/01/26 - 7:03
Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
27/01/26 - 16:05
The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
26/01/26 - 7:09
Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
23/01/26 - 17:49
Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
16/12/19 - 14:10
Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay (571.47 KB)
06/12/19 - 18:12
Press Release (262.61 KB)
06/12/19 - 18:11
Press Release (262.7 KB)
06/12/19 - 18:08
Communication on total amount of voting rights (281.87 KB)
27/11/19 - 7:59
DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET (531.97 KB)
11/11/19 - 9:46
DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET (159.93 KB)
06/11/19 - 13:00
Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019 (621.09 KB)
30/10/19 - 9:55
DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET (579.27 KB)
22/10/19 - 14:10
DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET (358.37 KB)
07/10/19 - 10:20
Communication on total amount of voting rights (282.21 KB)
24/09/19 - 10:10
DiaSorin launches VZV Direct molecular test in Europe (369.67 KB)
31/07/19 - 13:00
DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability. (687.57 KB)
10/06/19 - 18:23
DiaSorin presents its 2019-2022 Industrial Plan (548.2 KB)
05/06/19 - 7:38
DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease (448.98 KB)
29/05/19 - 15:06
DiaSorin launches VZV DIRECT molecular test in the United States (360.87 KB)
09/05/19 - 13:14
DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019 (728.82 KB)
06/05/19 - 15:19
DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL (416.77 KB)
30/04/19 - 12:28
Update Annual Calendar of Corporate Events 2019 (249.43 KB)
24/04/19 - 17:24
DiaSorin: Shareholders' Meeting 2019 (449.66 KB)
12/04/19 - 8:59
Communication on total amount of voting rights (320.44 KB)
05/04/19 - 9:33
Communication on total amount of voting rights (342.47 KB)
03/04/19 - 20:18
Lists publication (79.68 KB)
03/04/19 - 10:32
DiaSorin launches the anaemia panel on Liaison XL in Europe (416.47 KB)
14/03/19 - 14:16
Growth in revenues, profitability and net profit in 2018 (1.03 MB)
07/03/19 - 11:45
Communication on total amount of voting rights (350.08 KB)
06/03/19 - 8:45
A new Group website for DiaSorin: www.diasoringroup.com (154.5 KB)
07/02/19 - 15:15
Communication on total amount of voting rights (February 7, 2019) (349.86 KB)
31/01/19 - 22:30
DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market (528.02 KB)
03/01/19 - 13:30